AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical and biopharmaceutical company, has announced preliminary results from a late-stage study for its EGFR inhibitor, Tagrisso (osimertinib), in patients with unresectable, stage III EGFR-mutated non-small cell lung cancer (NSCLC) characterized by exon 19 deletions or exon 21 mutations. The trial successfully met its primary endpoint of progression-free survival (PFS), with the median PFS increasing to 39.1 months from 5.6 months in the placebo group.
These results indicate an 84% reduction in the risk of disease progression or death compared to placebo. The benefits were consistent across various demographics, including sex, race, type of EGFR mutation, age, smoking history, and prior chemoradiotherapy. The study did not raise any new safety concerns.
Tagrisso currently holds regulatory approvals for the treatment of locally advanced or metastatic EGFR-mutated NSCLC, locally advanced or metastatic EGFR T790M mutation-positive NSCLC, and early-stage EGFR-mutated NSCLC.- Flcube.com
